Patent Continuations: One Specification, Years of New Claims

A patent is often treated as a finish line: the application is filed, the patent issues, the work is done. For anyone building something competitors will eventually build too, that framing leaves real value on the table. The continuation is the mechanism that keeps a patent family alive for years after the first filing, and it is one of the most strategic tools in US patent practice.

Last updated: July 2026. This article provides general educational information about U.S. patent practice. It is not legal advice, does not create an attorney-client relationship, and should not be relied upon to determine filing strategy, deadlines, patentability, validity, inventorship, infringement, ownership, or legal rights. Any software features or outputs discussed are informational and drafting aids only; they do not make legal determinations or substitute for professional judgment. Consult a registered patent attorney or patent agent regarding prosecution matters and qualified legal counsel regarding ownership, licensing, enforcement, or other legal issues.

What a continuation actually is

A continuation application is a new application that pursues different or additional claims based on the disclosure of an earlier, copending ("parent") application. It generally carries forward the earlier application's specification and drawings, although revisions may be made so long as they do not introduce new matter. The continuation receives the benefit of an earlier filing date only for claimed subject matter adequately disclosed under §112(a) in the relevant earlier application and only if the other statutory requirements are satisfied. What principally changes is the claim set: the applicant seeks different claim language or scope based on the existing disclosure.

Two things make this powerful:

• Benefit of earlier filing date may be preserved. A continuation may receive the benefit of an earlier application's filing date under 35 U.S.C. §120 for claimed subject matter adequately supported by that application under §112(a), including the written-description and enablement requirements.
• No new matter may be introduced. A continuation cannot add disclosure that would constitute new matter relative to the parent. Claims lacking adequate support in the earlier disclosure are not entitled to the earlier filing date and may also fail §112.

The family: continuation, divisional, continuation-in-part

These three are frequently confused, and the differences are legally significant.

The CIP carries a trap worth stating plainly: claims that depend on newly added matter are not entitled to the parent's filing date and generally receive the CIP's later filing date. Filing-date entitlement must be evaluated claim by claim.

There is also a wrinkle from the America Invents Act (AIA). A CIP filed on or after March 16, 2013 becomes subject to the AIA first-inventor-to-file regime if it contains, or ever contained, a claim whose effective filing date, the date a claim is actually entitled to, which is the parent's only where the parent supports it, falls on or after that date, which is what happens when a claim depends on the new matter for support. A CIP whose claims are all fully supported by a pre-AIA parent does not automatically lose pre-AIA treatment, and mixed families get a more complicated answer still. Pre-AIA §102(g) can continue to apply alongside AIA §§102 and 103. Check the chain claim by claim rather than by filing date alone. See MPEP 2159.

The rules that make it work

• Copendency. A continuation must be filed while the parent is still pending, that is, on or before the date the parent patent issues. The Federal Circuit addressed same-day filing in Immersion. Once the parent issues, abandons, or proceedings terminate, that door is closed. Practitioners commonly file the continuation before paying the issue fee on the parent, which is why a well-run portfolio treats "file the continuation" as a checkpoint at allowance rather than an afterthought.
• A common inventor. For each claimed-benefit relationship in the chain, the later application must name at least one inventor or joint inventor named in the relevant prior application. Inventorship must nevertheless be correct for the claims pending in each application.
• An explicit reference chain. The continuation must specifically identify each prior application on which it relies and state the applicable relationship. The required reference and copendency must be maintained through the chain. See MPEP 211.
• Inventorship follows the new claims. At least one inventor must be shared for §120 benefit, but inventorship in the continuation is determined by what its claims actually cover. Because continuation claims often target a different embodiment or contribution, the named inventors may need to change, which in turn touches assignment paperwork, former employees and contractors, and chain of title. Code authorship is evidence of contribution, not the legal test: someone can conceive without implementing, and someone who only implements another's complete conception may not be an inventor. See AI and patent inventorship.
• Term runs from the earliest benefit claim. The 20-year term is generally measured from the earliest US non-provisional or qualifying international application in the benefit chain (§§120, 121, 365(c), 386(c)), not from the continuation's own filing date. A US provisional and a foreign priority claim generally do not start that clock. A continuation does not restart the term or extend the family's ordinary statutory term; it extends your ability to keep drafting new claims within it. Patent term adjustment (PTA) can add days to an individual patent, so "same clock" is the rule rather than an absolute.

A request for continued examination (RCE) is not a continuation. The two often get confused with one another. An RCE reopens prosecution in the same application; it does not create a new application or provide an unrestricted right to switch prosecution to an independent and distinct invention. A continuation, by contrast, is a new application with its own application number and claims, relying on the prior application's disclosure and, when the statutory requirements are satisfied, its filing-date benefit. An RCE may be used to present materially different claims supported by the existing disclosure, but not, as a matter of right, to replace the examined invention with an independent and distinct one. Claims directed to a nonelected or otherwise distinct invention generally should be pursued in a divisional or other continuing application.

The companion issue: double patenting and terminal disclaimers

Any discussion of continuations that stops at filing-date benefit and patent term is incomplete. Continuation claims may face obviousness-type double patenting (ODP) when they are not patentably distinct from claims in another patent or application having the relevant ownership, inventorship, applicant, or research relationship. A terminal disclaimer can often overcome an ODP rejection during prosecution, but it may disclaim any portion of the later patent's term extending beyond the relevant reference patent and ordinarily conditions enforceability on common ownership.

The interaction between ODP and patent term adjustment requires particular care. In In re Cellect (Fed. Cir. 2023), the Federal Circuit held that ODP is assessed using the patent's expiration date after PTA is included. The Supreme Court denied review in October 2024. In Allergan USA, Inc. v. MSN Laboratories (Fed. Cir. 2024), however, the Federal Circuit held that a first-filed, first-issued, later-expiring claim could not be invalidated for ODP based on a later-filed, later-issued, earlier-expiring claim sharing a common priority date. The Federal Circuit subsequently applied that rule in Acadia Pharmaceuticals Inc. v. Aurobindo Pharma Ltd. in 2025. The resulting analysis depends on filing order, issuance order, expiration dates, claim scope, and the source of any term difference; it should not be reduced to a general rule that every later family member must surrender PTA. See the Federal Circuit's Allergan opinion. For the decided cases on how far a continuation's claims can reach, see what the Federal Circuit has held about continuation claims.

A terminal disclaimer is not a free fix. In addition to disclaiming any applicable terminal portion of the patent term, it typically conditions enforceability on the patents remaining commonly owned, which matters later during spinouts, acquisitions, portfolio sales, and any attempt to license or assign family members separately. A continuation is not just another claim set; it is a new asset with potential consequences for how the whole family can be transferred. The USPTO proposed going further in May 2024, conditioning a terminal-disclaimed patent's enforceability on the validity of claims in the patent it was disclaimed against, then withdrew that proposal in December 2024 after more than 300 comments. The existing common-ownership condition is what applies.

One related trap for the divisional column above: the §121 safe harbor against double patenting is not automatic just because an application is labeled a divisional. It generally depends on the divisional being filed in response to a restriction requirement, the examiner requiring that an application covering more than one independent invention be split, filed while the parent is pending, and maintaining consonance with the restricted groups, meaning the claims stay lined up with the inventions as the examiner divided them. General framework: MPEP 804.

The sharpest reason: disclosed but unclaimed can be dedicated to the public

The disclosure-dedication doctrine is an important reason to consider continuation claims, but its effect should be stated precisely. Under Johnson & Johnston Associates v. R.E. Service Co., 285 F.3d 1046 (Fed. Cir. 2002) (en banc), subject matter disclosed as an alternative to a claim limitation but unclaimed may be treated as dedicated to the public for purposes of the doctrine of equivalents.

In Johnson & Johnston, the specification disclosed both aluminum and steel substrates, but the asserted claims recited aluminum. The patentee could not use the doctrine of equivalents to expand those claims to cover the disclosed but unclaimed steel alternative.

The doctrine does not make the disclosed subject matter unpatentable, invalidate a pending continuation, or prevent an applicant from seeking literal claims to that subject matter in a properly pending application. Its consequence is narrower: an issued claim generally cannot rely on the doctrine of equivalents to recapture a sufficiently disclosed alternative that the patentee chose not to claim.

Continuation practice can address that risk by allowing an applicant to seek literal claims directed to commercially relevant alternatives already supported by the disclosure, subject to filing-date entitlement, patentability, inventorship, and the other applicable requirements.

The practical question at allowance is therefore: which commercially relevant alternatives does the specification disclose that the family has not yet claimed, and should any of them be evaluated by a registered patent practitioner for possible continuation claims?

The line worth remembering is this: a continuation is not a second chance to add what the original application omitted. It is an opportunity to seek additional claims based on what the application adequately disclosed.

Why they matter: the strategic case

A continuation is optionality. You paid to write a rich specification once; a continuation lets you keep drawing on that disclosure as the world changes.

• Respond to later market developments. If a later product or design-around practices subject matter supported by the original disclosure, an applicant may seek claims that cover it. In Kingsdown Medical Consultants, Ltd. v. Hollister Inc. (Fed. Cir. 1988), the court explained that it is not improper merely to amend or present claims intended to cover a competitor's product, provided the claims satisfy the applicable legal requirements. Whether particular claims are supported, patentable, properly invented, enforceable, and strategically appropriate remains a matter for professional legal judgment. Separately, prosecution laches may apply in exceptional circumstances involving unreasonable and unexplained prosecution delay that causes prejudice. The Federal Circuit reaffirmed the doctrine in the Hyatt litigation, and the Supreme Court denied review on June 29, 2026.
• Adjust scope as the invention proves out. Continuation claims can be broader or narrower than the parent's. Early claims are often conservative; a continuation lets you go broader once you understand what actually matters, or narrower and more defensible once you see the prior-art landscape. Our Claim Scope Ladder can help organize candidate claim concepts, map them to potentially relevant portions of the disclosure, and flag possible support or patentability issues for practitioner review. It does not determine §112 compliance, validity, patentability, or appropriate claim scope.
• Preserve claim flexibility. Maintaining a pending continuation preserves the applicant's ability to pursue additional supported claims as technology and the market develop. Pendency may create some uncertainty for third parties, but it does not prevent competitors from evaluating the published disclosure, monitoring prosecution, or attempting to design around existing and reasonably foreseeable claim scope.
• Portfolio value. A single well-drafted specification can become a multi-patent family with years of claim flexibility, which is part of why acquirers and licensees look at whether continuations are still pending.

The mental model that captures it: the specification is the asset, and each continuation is a fresh option written against that asset while the clock runs. That is also why the quality of the original disclosure matters so much. See how to write a strong disclosure and the Invention Disclosure Form.

Where AI helps, and where it does not

Continuation drafting is well suited to AI assistance for a specific reason: the relevant technical disclosure already exists in a specification. The task often is to find subject matter disclosed in the specification but not expressly captured by issued claims, and to draft that subject matter in proper claim form. That is a language task grounded in a fixed document, which is where current models are at their strongest.

An AI drafting aid can surface disclosed but potentially unclaimed subject matter across a long specification faster than a manual re-read, draft candidate claim sets in conventional USPTO claim format, map proposed claim limitations to potential written-description support, flag possible antecedent-basis and definiteness issues, and compare proposed claims with the parent's claims. These functions can materially accelerate a practitioner's review, but they do not establish written-description support, definiteness, patentability, validity, or commercially appropriate claim scope. Those are legal and strategic determinations that remain with the registered patent practitioner.

The limits have to be stated as plainly as the capabilities:

• Fluency is not support. A model can draft polished claim language directed to an embodiment or combination that the specification does not adequately disclose. Citation to related passages is useful evidence for review, not a legal determination that §112(a) is satisfied.
• AI does not determine patentability. Novelty and non-obviousness require analysis of the claims against the relevant prior art, informed by legal judgment. Eligibility, definiteness, written-description support, enablement, inventorship, and other requirements likewise cannot be established by a drafting score or automated check. A tool that flags drafting issues or compares claims is not predicting that a claim will be allowed or upheld. See the §103 worksheet and the §101 worksheet for the analyses that do sit with counsel.
• The practitioner remains responsible for the filing. Under the USPTO's Guidance on Use of AI-Based Tools in Practice Before the USPTO, applicable April 11, 2024, the existing duties continue to apply when AI tools are used. These include the duty of candor and good faith, the duty to make a reasonable inquiry, and the certifications associated with presenting a paper under 37 CFR 11.18. A practitioner must independently review any AI-assisted work product before submitting it and remains professionally responsible for the filing.
• Confidentiality and security still matter. Before providing unpublished applications, invention disclosures, source code, or client information to an AI system, the practitioner must evaluate the system's data-use, retention, access, and security terms and comply with applicable confidentiality obligations and client instructions.

That is the appropriate posture: an AI tool can help organize documents, generate candidate language, map limitations to potentially relevant passages, and flag issues for review. These functions are informational and assistive only. The tool does not provide legal advice, determine legal rights, or recommend whether a continuation should be filed. Users should not rely on its output to make filing, deadline, patentability, inventorship, ownership, infringement, or enforcement decisions. Those decisions should be made by the applicant in consultation with a registered patent practitioner or other qualified counsel, as appropriate. Related: AI and patent inventorship.

When a continuation is not worth filing

The ability to file a continuation is not, by itself, a reason to file one. Not every allowance should produce another application. The decision should turn on the value and defensibility of the particular claim scope under consideration, including:

• Disclosure support and priority. Whether the original disclosure adequately supports the proposed claims under §112(a), and which filing date those claims are actually entitled to receive.
• Commercial relevance. Whether the proposed scope covers a meaningful product, feature, design-around, licensing opportunity, or competitive development, or is merely unclaimed subject matter that happens to be available.
• Remaining patent term. For a typical modern continuation, the statutory term is generally measured from the earliest application for which domestic benefit is claimed under 35 U.S.C. §§120, 121, 365(c), or 386(c), not from the continuation's filing date. A continuation filed late in the family's life may therefore provide only a short period of enforceable exclusivity. See MPEP 2701.
• Patentability and validity risk. The proposed claims' exposure under §§101, 102, 103, and 112, including the prior art developed during prosecution of the family and any additional art relevant to the new scope.
• Detectability and proof of infringement. Whether infringement could be observed and proved using information reasonably available from the accused product or service. Claims requiring access to internal operations, server-side activity, or conduct divided among multiple actors may be considerably less valuable.
• Inventorship and ownership. Whether changing the claimed subject matter changes the proper inventorship, and whether assignments and other ownership records cover the resulting rights. Inventorship must be evaluated against the claims actually pursued.
• Double patenting and terminal disclaimers. Whether obviousness-type double patenting is likely and, if so, whether a terminal disclaimer would shorten the effective term or require common ownership with another patent as a condition of enforceability. That requirement can complicate separate assignments, licensing arrangements, and enforcement strategy. See MPEP 1490.
• Cost and expected value. Whether filing, prosecution, issuance, maintenance, portfolio-management, and potential enforcement costs are justified by the expected commercial value of the claims.
• The boundary of the original disclosure. Whether the proposed claims are supported by the application as originally filed. A later-developed implementation need not necessarily have been described verbatim, but missing disclosure cannot be supplied through a continuation. If the desired claims depend on genuinely new subject matter, a continuation cannot preserve the earlier filing date for that subject matter; a new application or continuation-in-part may need to be considered.

Timing also matters. A continuation must be filed while the required copendency with the prior application still exists. The strategic decision therefore should be made before issuance or abandonment closes the relevant branch of the family.

Continuation practice is flexible, but bounded. A continuation cannot add new matter; entitlement to an earlier filing date depends on adequate disclosure support for the claimed subject matter; filing a continuation does not ordinarily restart the patent-term clock; and double-patenting doctrine limits unjustified extension of exclusivity. In unusual cases, an unreasonable and prejudicial delay in presenting claims may also create prosecution-laches risk.

An AI tool can help organize these considerations, identify candidate claim scope, and surface issues for review. It cannot decide whether filing a continuation is legally or commercially advisable. That decision belongs to the applicant, informed by the independent judgment of a registered patent practitioner.

The takeaway

A continuation can make a single disclosure a more durable and adaptable portfolio asset. It allows a patent family to pursue claim scope responsive to later market developments, competing products, and design-arounds, while remaining bounded by the original disclosure, the family's patent term, and applicable double-patenting constraints. AI can accelerate the document-intensive work of identifying candidate subject matter, generating claim language, mapping limitations to potentially supporting disclosure, and flagging drafting issues. It cannot determine support, patentability, validity, inventorship, infringement, or appropriate claim strategy. Those determinations require the independent judgment of a registered patent practitioner, who must review and take responsibility for the resulting work product.

Filing your first application rather than extending a family? Start with provisional patent strategy.

Sources